We describe the clinical characteristics and outcomes of 16 children and young adults with severe acute COVID-19 who were treated with tocilizumab. Patients who were discharged by day 28 were more likely to be treated with tocilizumab earlier in their COVID-19 illness and had lower ferritin and interleukin-6 levels compared with those who were not discharged by day 28.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838604 | PMC |
| http://dx.doi.org/10.1097/INF.0000000000003763 | DOI Listing |
Publication Analysis
Top Keywords
children young
8
young adults
8
adults severe
8
severe acute
8
acute covid-19
8
treated tocilizumab
8
discharged day
8
tocilizumab treatment
4
treatment children
4
covid-19 experience
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!